Yuxian Bai Selected Research

human TNFSF10 protein

1/2018

Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yuxian Bai Research Topics

Disease

31	Neoplasms (Cancer) 04/2022 - 07/2010
14	Hepatocellular Carcinoma (Hepatoma) 07/2022 - 10/2013
14	Stomach Neoplasms (Stomach Cancer) 04/2022 - 09/2013
13	Colorectal Neoplasms (Colorectal Cancer) 10/2021 - 06/2015
12	Disease Progression 01/2022 - 02/2014
12	Hypertension (High Blood Pressure) 11/2021 - 06/2015
9	Esophageal Squamous Cell Carcinoma 01/2022 - 01/2019
6	Esophageal Neoplasms (Esophageal Cancer) 11/2021 - 01/2018
5	Carcinoma (Carcinomatosis) 01/2022 - 02/2014
5	Proteinuria 11/2021 - 01/2017
5	Neoplasm Metastasis (Metastasis) 10/2021 - 10/2016
5	Adenocarcinoma 01/2021 - 10/2014
4	Anemia 01/2021 - 01/2019
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 04/2022 - 07/2010
3	Neutropenia 01/2021 - 01/2019
3	Leukopenia 01/2021 - 01/2019
3	Nausea 08/2020 - 01/2019
2	Diarrhea 01/2022 - 08/2020
2	Cholangiocarcinoma 11/2021 - 01/2020
2	Hand-Foot Syndrome 01/2021 - 01/2019
2	Liver Neoplasms (Liver Cancer) 01/2021 - 11/2017
2	Pancreatic Neoplasms (Pancreatic Cancer) 12/2020 - 11/2014
2	Renal Cell Carcinoma (Grawitz Tumor) 01/2020 - 01/2019
2	Exanthema (Rash) 06/2015 - 10/2014
2	Breast Neoplasms (Breast Cancer) 05/2014 - 01/2013
1	Neuroendocrine Tumors (Neuroendocrine Tumor) 01/2022
1	Dyspnea (Shortness of Breath) 01/2022
1	Gallbladder Neoplasms (Gallbladder Cancer) 11/2021
1	Biliary Tract Neoplasms (Biliary Tract Cancer) 11/2021
1	Blister (Bulla) 11/2021
1	Hyperkalemia 01/2021
1	Hypesthesia (Numbness) 01/2021
1	Hyponatremia 01/2021
1	Intestinal Volvulus (Volvulus) 01/2021

Drug/Important Bio-Agent (IBA)

8	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2021 - 10/2013
8	Fluorouracil (Carac)FDA LinkGeneric 08/2020 - 10/2013
7	Biomarkers (Surrogate Marker)IBA 04/2022 - 10/2014
7	Capecitabine (Xeloda)FDA Link 01/2021 - 02/2014
6	anlotinibIBA 10/2021 - 01/2019
6	Cisplatin (Platino)FDA LinkGeneric 03/2020 - 10/2014
5	Monoclonal AntibodiesIBA 01/2022 - 01/2020
5	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 11/2021 - 10/2016
5	HMPL-013IBA 05/2021 - 01/2017
5	apatinibIBA 01/2021 - 09/2013
5	Leucovorin (Folinic Acid)FDA Link 10/2018 - 10/2013
4	Bevacizumab (Avastin)FDA Link 01/2022 - 01/2021
4	Proteins (Proteins, Gene)FDA Link 01/2022 - 07/2010
4	surufatinibIBA 01/2022 - 11/2020
4	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 11/2021 - 01/2017
4	1-phenyl-3,3-dimethyltriazene (PDT)IBA 11/2021 - 01/2018
4	camrelizumabIBA 09/2021 - 01/2020
4	Sorafenib (BAY 43-9006)FDA Link 07/2021 - 01/2021
3	Paclitaxel (Taxol)FDA LinkGeneric 01/2022 - 02/2014
3	BilirubinIBA 11/2021 - 01/2021
3	Aspartate Aminotransferases (Aspartate Transaminase)IBA 08/2020 - 06/2015
3	Tyrosine Kinase InhibitorsIBA 01/2020 - 05/2016
3	artenimol (dihydroartemisinin)IBA 07/2019 - 01/2018
2	lenvatinibIBA 07/2022 - 05/2021
2	Caspase 3 (Caspase-3)IBA 01/2022 - 11/2021
2	Caspase 8 (Caspase-8)IBA 01/2022 - 11/2021
2	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2021
2	sintilimabIBA 01/2022 - 01/2021
2	atezolizumabIBA 01/2022 - 07/2021
2	Pharmaceutical PreparationsIBA 01/2022 - 08/2020
2	Photosensitizing Agents (Photosensitizers)IBA 11/2021 - 01/2021
2	ErbB Receptors (EGF Receptor)IBA 10/2021 - 10/2014
2	AcidsIBA 12/2020 - 11/2017
2	Pyruvate KinaseIBA 10/2020 - 07/2019
2	regorafenibIBA 08/2020 - 06/2015
2	Alanine Transaminase (SGPT)IBA 08/2020 - 06/2015
2	Docetaxel (Taxotere)FDA Link 03/2020 - 01/2016
2	tislelizumabIBA 01/2020 - 01/2020
2	LigandsIBA 01/2020 - 01/2018
2	human ERBB2 proteinIBA 01/2019 - 02/2016
2	Trastuzumab (Herceptin)FDA Link 01/2019 - 02/2016
2	Irinotecan (Camptosar)FDA LinkGeneric 01/2019 - 08/2018
2	Cetuximab (Erbitux)FDA Link 10/2018 - 10/2014
2	artemisinin (artemisinine)IBA 01/2018 - 01/2018
2	Doxorubicin (Adriamycin)FDA LinkGeneric 11/2014 - 10/2013
1	1- (1- (imidazo(1,2- a)pyridin- 6- yl)ethyl)- 6- (1- methyl- 1H- pyrazol- 4- yl)- 1H- (1,2,3)triazolo(4,5- b)pyrazineIBA 04/2022
1	Growth Factor ReceptorsIBA 01/2022
1	pembrolizumabIBA 01/2022
1	alpha-Fetoproteins (alpha-Fetoprotein)IBA 01/2022
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2022
1	RNA (Ribonucleic Acid)IBA 01/2022
1	Sincalide FDA Link 01/2022
1	B7-H1 AntigenIBA 01/2022
1	InflammasomesIBA 10/2021
1	CytokinesIBA 10/2021
1	XELOXIBA 07/2021
1	Death Domain ReceptorsIBA 01/2021
1	zimberelimabIBA 01/2021
1	CurcuminIBA 01/2021
1	penpulimabIBA 01/2021

Therapy/Procedure

20	Therapeutics 01/2022 - 10/2014
19	Drug Therapy (Chemotherapy) 01/2022 - 09/2013
6	Photochemotherapy (Photodynamic Therapy) 01/2022 - 11/2017
3	Immunotherapy 01/2022 - 07/2010
3	Microbubbles 01/2021 - 11/2017
1	Intravenous Infusions 01/2022